Potential Treatment for Generalized Myasthenia Gravis (gMG)
Trial Summary
What is the purpose of this trial?
MG is a rare autoimmune disease affecting about 700,000 people worldwide. The current therapy for MG focuses on treating symptoms caused by the disease, such as muscle weakness. The UPSTREAM MG Clinical Study will test how safe and effective a study drug called telitacicept may be in adults living with generalized myasthenia gravis (gMG).
Why do researchers think this study treatment might be promising?
New clinical studies to evaluate MG treatment are shifting from symptom relief to targeting the immune system when it is overactive in an abnormal way, which is the root cause of MG. The UPSTREAM MG Clinical Study is testing the safety and efficacy of a study drug that targets the immune system to see what effect it may have on the daily lives of those who have MG.
Timeline
Screening
Participants are evaluated to confirm eligibility
Double Blind Period
Weekly injections of active study drug or placebo - either on-site or at home.
Open Label Extension
Optional study extension where all patients can receive the study drug. The open label extension will continue until the drug is approved.
Follow-up
Participants are monitored after completing treatment.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.